Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle
Authors:
Open Access
- 19 May 2025
- journal article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 51 (3) , e70019
Abstract
Aims: Diagnosis of inclusion body myositis (IBM) is difficult and currently based on a combination of clinical and (immuno)histological findings. Biomarkers facilitating the diagnostic process are needed. Alpha‐synuclein (αSN) aggregates are a known histological feature of IBM, but there is a lack of information on their diagnostic relevance. Furthermore, serum αSN concentrations in IBM have not been investigated.Methods: Immunohistochemical staining for αSN was performed on 63 biopsies (19 IBM, 21 other inflammatory myopathies, 20 other myopathies and 3 healthy controls), and αSN reactive fibres were quantified. The serum concentration of αSN was determined by ELISA in 156 serum samples (11 IBM, 25 other inflammatory myopathies, 53 hereditary myopathies, 30 mitochondriopathies and 37 healthy controls).Results: The proportion of fibres with αSN immunoreactivity was significantly higher in IBM compared to all groups (p < 0.001) and discriminated IBM against all other neuromuscular disorders with a sensitivity of 79% and a specificity of 85%, which further improved when only non‐regenerating fibres were examined. In serum, αSN concentrations in IBM were generally not different from healthy controls. However, serum concentrations were inversely correlated with disease duration (r = −0.62, p = 0.04) and positively correlated with the IBM functional rating scale (r = 0.74, p = 0.01). Consequently, stratification according to these clinical parameters showed significantly lower serum αSN concentrations in late‐stage, more severely affected patients.Conclusions: αSN reactivity may serve as an additional immunohistochemical marker for IBM diagnosis. Furthermore, this study indicates that αSN serum concentrations decrease with disease duration and clinical deterioration. Therefore, serum αSN may be provisionally considered a monitoring biomarker in IBM, pending further studies.Keywords
Funding Information
- European Commission (MOODMARKER 01EW2008)
- Deutsche Forschungsgemeinschaft (SFB1279)
- Fondation Thierry Latran (10.13039/100009281)
This publication has 73 references indexed in Scilit:
- Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositisJournal of Neuroimmunology, 1997
- α-Synuclein in Lewy bodiesNature, 1997
- Treatment of inclusion-body myositis with IVIgNeurology, 1997
- Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapyBrain, 1997
- Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathiesEuropean Journal of Immunology, 1994
- The αβ T-Cell Receptor Repertoire in Inclusion Body Myositis: Diverse Patterns of Gene Expression by Muscle-infiltrating LymphocytesJournal of Autoimmunity, 1994
- Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.1994
- The Treatment of Inclusion Body MyositisMedicine, 1993
- Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophyNeuroscience Letters, 1991
- Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminalThe Journal of Neuroscience, 1988